---

$1.51

-0.0200 ( -1.31% ) 0.5K

Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B. We believe that the blockade of GSK-3B signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. We have exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University (NU). The lead drug in our portfolio is called elraglusib (9-ING-41), which is being evaluated in a randomized Phase 2 trial in patients with metastatic pancreatic cancer, our most advanced clinical indication to date

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2025-06-30	Buy	71428.00	Fletcher Aaron G.L.
2025-06-30	Buy	71428.00	Kreis Leslie W.
2025-06-30	Buy	71428.00	Bios Equity COF, LP
2024-08-14	Buy	884427.00	Bios Equity COF, LP
2024-08-14	Buy	884427.00	Fletcher Aaron G.L.
2024-08-14	Buy	884427.00	Kreis Leslie W.